About Apcintex
Apcintex is a Healthcare company based in Cambridge (United Kingdom) founded in 2014, and was acquired by Centessa Pharmaceuticals in February 2021. Anti-coagulant targeting APC pathway is developed for haemophilia treatment. Apcintex has raised $17.5 million across 1 funding round from investors including Cambridge Enterprise, Centessa Pharmaceuticals and Touchstone Innovations. The company has 2 employees. The company was acqui-hired. Its focus areas include Life Sciences, Rare Diseases, Drugs and Hematology. Its legal entity is APCINTEX LIMITED.
Company details
Based on the work of Professor Jim Huntington (Cambridge Institute for Medical Research) and Dr Trevor Baglin (Cambridge University Hospitals), Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia, including those who develop antibodies to replacement factors.
- Headquarters Cambridge, United Kingdom
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website apcintex.com
- Acquired by Centessa Pharmaceuticals (Feb 2021)
- Legal Name Apcintex Limited
- Date of Incorporation 16 Jun, 2014
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
- Total Equity Funding$17.5M (USD)
in 1 rounds
- Latest Funding Round$17.5M (USD), Series A
Feb 2017
- InvestorsCambridge Enterprise
& 3 more
- Employee Count2
- Acquired byCentessa Pharmaceuticals
(Feb 2021)
Funding Insights of Apcintex
Apcintex has successfully raised a total of $17.5M through 1 strategic funding round. The most recent funding activity was a Series A round of $17.5 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.5M
- Total Rounds 1
- Last Round Series A — $17.5M
- First Round $17.5M
(Feb 2017)
- Investors Count 3
All 1 funding rounds of Apcintex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $17.5M | Series A | – | Medicxi, Touchstone Innovations |
4 investors in total: 4 institutional.
Investors in Apcintex
Apcintex has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Cambridge Enterprise, Centessa Pharmaceuticals and Touchstone Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life science focused VC firm investing in geographies such as Europe and the US | medicxi.com | London, United Kingdom | ||
Provider of intellectual property management and technology consulting services | 2006 | enterprise.cam.ac.uk | Cambridge, United Kingdom | |
Creates, builds and invests in pioneering technology companies spun-out from Univs Cambridge, Oxford, and UCL | 1986 | touchstoneinnovations.com | London, United Kingdom | |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed. | 2021 | centessa.com | Boston, United States |
Investor details for Apcintex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Apcintex
3 dated milestones of Apcintex across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Apcintex is founded.
- Funding First funding round of $17.5M.
- Exit Acquired by Centessa Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apcintex
Complete news archive for Apcintex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apcintex
Apcintex was founded in 2014 and raised its 1st funding round 3 years after it was founded.
Apcintex is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Apcintex is a funded company, having raised a total of $17.5M across 1 funding round to date. The company's 1st funding round was a Series A of $17.5M, raised on Feb 2017.
Apcintex has 2 employees.
Based on the work of Professor Jim Huntington (Cambridge Institute for Medical Research) and Dr Trevor Baglin (Cambridge University Hospitals), Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia, including those who develop antibodies to replacement factors.
Apcintex has 4 investors. Key investors include Cambridge Enterprise, Centessa Pharmaceuticals, Touchstone Innovations, and Medicxi.
Apcintex operates through Apcintex Limited.
Yes. Apcintex was acquired by Centessa Pharmaceuticals in February 2021.